10/21/2026
In today’s episode of Eye on the Cure, host Maddie Mossman sits down with Dr. Daniel Chung, Chief Medical Officer of Beacon Therapeutics, to discuss Laru-zova, an emerging gene therapy that showed encouraging results in a Phase 3 clinical trial, including improvements in low-light vision.
Dr. Chung explains how the potential treatment works, what the latest findings mean for the XLRP community, and what’s next as Beacon prepares to begin a rolling FDA submission later this year.
The Foundation Fighting Blindness funded preclinical research that helped pave the way for Laru-zova. We’re proud to see how research can move from the lab toward potential treatments for people living with blinding diseases.
Listen to Episode 104 of Eye on the Cure today: https://bit.ly/47zAius
Image Description: Dark blue background with Foundation Fighting Blindness logo and the Eye on the Cure Podcast logo in the top left. Text "New Episode Out Now" is in the top right corner. Below are headshots of Alicia Kemble and Maddie Mossman with text underneath that says, "With Dr. Daniel Chung, October 21, 2026."